Avanos Medical, Inc. (AVNS)

In the past six months, Avanos Medical, Inc. announced its Fourth Quarter and Full-Year 2025 Results, which led to a -10.44% change in stock price. The company presented at the 2026 Citizens Life Sciences Conference and announced the nomination of James Cunniff and William Burke to its Board of Directors. CMS maintained NOPAIN Act eligibility for ON-Q* and ambIT* Infusion Pumps and added Game Ready* in 2026, which could positively impact future revenue streams. A collaboration with Siemens Healthineers was announced to advance integrated solutions for outpatient and interventional pain management. SEC filings showed new stock options and RSU awards for the CEO, CFO, and SVPs.

Avanos Medical, Inc. does not explicitly report significant demand seasonality for its products and services. The company has consistently reported "continued strong demand" for its Specialty Nutrition Systems (SNS) products and "sustained momentum in RFA generator sales" in the Pain Management & Recovery (PM&R) segment.

Avanos Medical, Inc. is a medical technology company that develops, manufactures, and markets medical device solutions for healthcare providers and patients globally, operating in the Healthcare sector, specifically in the Medical Devices and Healthcare Equipment & Supplies industry. The company focuses on Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments, offering products like Mic-Key enteral feeding tubes, ON-Q surgical pain pumps, and COOLIEF chronic pain products.

Avanos Medical, Inc. has a global presence across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company's headquarters is located in Alpharetta, Georgia, USA, and it maintains offices and operations in various countries, including the United Kingdom, Belgium, France, Netherlands, Sweden, Germany, Portugal, Japan, Singapore, Australia, and India.

Within the past year, no specific events that negatively impacted Avanos Medical, Inc.'s brand reputation were found. The company has focused on strategic transformations, portfolio shaping through divestitures and acquisitions, and emphasizing its commitment to patient health through its core solutions.

Avanos Medical, Inc.'s ownership is predominantly institutional, with institutional investors holding approximately 91.14% of the company's stock. Insiders hold a smaller portion, around 2.06% to 2.33% of the stock. Key institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and T. Rowe Price Investment Management, Inc.